Pfizer has reported a 30% operational growth in revenues to $100.3bn in full-year 2022 compared with $81.2bn reported last year.

The revenues grew 2% operationally excluding Paxlovid and Comirnaty’s contributions.

In the fourth quarter (Q4) of 2022, they increased 13% operationally to $24.3bn compared to $23.8bn in the same quarter last year.

On an operational basis, the revenues rose by 5%, omitting contributions from Paxlovid and Comirnaty.

The reported diluted EPS for full-year 2022 stood at $5.47, compared to $3.85 in the prior year, indicating a 42% growth.

A 62% rise in adjusted diluted EPS to $6.58 was reported last versus $4.06 in 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For Q4 2022, the reported diluted EPS stood at $0.87 as against $0.59 in the year-ago quarter, indicating a 48% rise.

The company reported a 45% growth in adjusted diluted EPS to $1.14 in the quarter compared to $0.79 in the prior-year quarter.

Pfizer chairman and CEO Dr Albert Bourla said: “2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history but more importantly, in terms of the percentage of patients who have a positive perception of Pfizer and the work we do.

“As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.

“We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond.”

This content was updated on 25 January 2024